Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company specializing in macrophage reprogramming for anticancer immunotherapies, has announced that John Poulos, a Non-executive Director of the company, sold 5,000 ordinary shares in Faron on October 3, 2023, at a price of 3.7209 per share, and on October 12, 2023, sold another 5,000 ordinary shares at a price of 3.8259 per share. Following these transactions, Poulos now holds 10,000 ordinary shares in the company, representing 0.02% of the issued share capital.

The notification of these transactions has been made in accordance with the requirements of the EU Market Abuse Regulation. The details of the transactions, including the financial instrument, nature of the transaction, price, volume, date, and place of the transaction, have been provided in the announcement.

For more information, investors can contact LifeSci Advisors, Cairn Financial Advisers LLP, Peel Hunt LLP, or Sisu Partners Oy, the Certified Adviser on Nasdaq First North.

Faron Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing macrophage reprogramming for effective anticancer immunotherapies.